TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Company Performance - TG Therapeutics (NASDAQ: TGTX) was rated a buy in March 2024, with the first four quarters of sales of their multiple sclerosis drug, Briumvi, making their 2024 sales guidance seem achievable [1] Industry Focus - The company operates in the biotech industry, with a focus on trading around events such as trial results and NDA/BLA approvals [1] - The industry is regulated by the FDA, which is a key factor in the company's operations and product development [1]